(Reuters) - The company had a net loss C$6.5 million, or 11 Canadian cents a share, compared with a loss of C$6.8 million, or 16 Canadian cents a share in the corresponding period a year earlier.
Revenue rose to C$5.4 million from C$4.3 million, lifted by the launch of Labopharm's Tramadol pain medication in France, United Kingdom, Spain and Belgium.
Read more at Reuters.com Market News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment